Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Treatment landscape for metastatic hormone-sensitive prostate cancer

Andrew J. Amstrong, MD, Duke Cancer Institute, Durham, NC, discusses the current treatments for patients with metastatic hormone-sensitive prostate cancer. A range of options are now available, including chemo-hormonal therapy, docetaxel androgen deprivation therapy (ADT), and androgen receptor (AR) inhibitors. Treatment decisions can be made based on an individual’s disease characteristics, genotype, pattern of spread, and risk, allowing patients to live longer and sometimes stop treatment after going into remission. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Dr Armstrong reports research support (to Duke) from the NIH/NCI, PCF/Movember, DOD, Astellas, Pfizer, Bayer, Janssen, Dendreon, Genentech/Roche, BMS, AstraZeneca, Merck, Constellation, Beigene, Forma, Celgene, Amgen.

Dr Armstrong reports consulting or advising relationships with Astellas, Pfizer, Bayer, Janssen, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Clovis, Exact Sciences.